You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
醫藥板塊跑輸大市 開拓藥業(09939.HK)及先聲藥業(02096.HK)挫13%
遭大股東折讓3.9%每股71元減持5,600萬股的藥明生物(02269.HK)午後跌幅擴大,最低見68.6元,現報69.35元,回吐6.2%。藥明康德(02359.HK)由半年高位回吐3.77%曾低見99.3元。諾輝健康-B(06606.HK)由逾一年高位回吐5%,曾低見31.2元。 醫藥股今天沽壓遠超大市(恆指回吐1.1%),尤其是開拓藥業-B(09939.HK)跌破20天及10天線,午後低見10.12元,現報10.32元,急吐13%,成交已達1,843萬股;先聲藥業(02096.HK)繼今天跌破10天線,最低見11.48元,現報11.62元,續吐13%,成交增至8,513萬股。 國藥(01099.HK)、東曜藥業-B(01875.HK)、神威藥業(02877.HK)、三葉草生物-B(02197.HK)、榮昌生物-B(09995.HK)、康醫療-B(02170.HK)、康希諾(06185.HK)及騰盛博藥-B(02137.HK)跌近4%至6.6%。 此外,國家藥監局公布部署各地藥品監管部門持續加強對疫情防控相關藥械的質量監管,加大對製售涉疫藥械違法犯罪行為的打擊力度。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account